)
Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Kratz F, Drevs J, Bing G, Stockmar C, Scheuermann K, Lazar P, Unger C: Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates
Who is (and is not) a candidate for PT-141
The GLP-1 market is expected to ramp up from $75bn at present to $200bn by the early 2030s, JPMorgan Chase analysts predict
Zhang J, Lu H, Zeng H, et al
1 Introduction Vascular injury represents a substantial health risk, particularly in critically ill patients in the ICU, where it often leads to complex complications that significantly worsen prognosis (Gao et al., 2021
US$ 21.89
US$ 26.35
US$ 29.42
US$ 26.75
US$ 24.06
US$ 25.46
